Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor - HEM Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03439839 (CLNP023X2201) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 16 Reduction of chronic hemolysis, based on LDH level at Week 13 10 patients receiving LNP023 high dose daily over up to approximately 3 years 5 patients receiving LNP023 low dose daily over up to approximately 3 years Patients with PNH, showing signs of active hemolysis despite treatment with SoC (defined as an antibody with anti C5 activity). Primary: Q2-2020 (actual) Extension: 2023 Antonio M. Risitano, MD, PhD1 et al. Presented at EBMT 2020 congress Jan 2021Pubs: Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial, Risitano, Antonio M et al. The Lancet Haematology, Volume 8, Issue 5, e344 - e354 NCT03896152 (CLNP023X2204) Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 13 Reduction of PNH associated hemolysis, based on percentage of patients with 60% reduction in LDH or LDH below upper limit of normal up to 12 weeks of treatment. approximately 2 year Treatment with low LNP023 dose approximately 2 year Treatment with higher LNP023 dose Patients with PNH, showing signs of active hemolysis, not treated with any other complement inhibitor less than 3 months prior to study start Day 1 Primary: Q2-2020 (actual) Extension: 2022 -Jang JH, et al. Presented at Korean Society of Hematology International Conference and 62nd Annual Meeting (ICKSH 2021) -Presented as an oral presentation (encore) at the European Haematology Association (EHA 2021) congress -Planned manuscript submission in Q3 2021 126 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation